Delving into the Latest Updates on Proveca Pharma Ltd. with Synapse

Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,

Double blind, placebo-controlled, randomised trial, multicentre in France with open-label tolerability phase.
The double-blind placebo-controlled study duration will be scheduled for 3 months with the final visit of the double-blind period at D84. After the D84 assessment, patients will be invited to continue into a 6-month openlabel study extension (OLSE) with ex-Sialanar® patients continuing the treatment and ex-placebo patients starting Sialanar®

开始日期2021-05-10

申办/合作机构

Proveca Pharma Ltd.

EUCTR2020-005534-15-FR / Unknown status临床4期

Double-blind, placebo-controlled, randomized clinical trial comparing the efficacy and safety of Sialanar plus oral rehabilitation against placebo plus oral rehabilitation for children and adolescents with severe sialorrhoea and neurodisabilties - SALIVA study

开始日期2021-04-01

申办/合作机构

Proveca Pharma Ltd.

100 项与 Proveca Pharma Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Proveca Pharma Ltd. 相关的专利（医药）

登录后查看更多信息

100 项与 Proveca Pharma Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Proveca Pharma Ltd. 相关的转化医学

登录后查看更多信息